In April 2022, we amended our lease and development agreement with
PharmaCann at one of our New York properties, increasing the
construction fund by $45.0 million to a total of approximately
$78.5 million, which also resulted in a corresponding adjustment to
the base rent for the lease at the property.
In June 2022, we amended our lease with a subsidiary of Curaleaf
Holdings, Inc. (“Curaleaf”) at one of our Illinois properties,
increasing the improvement allowance under the lease by
approximately $10.9 million to a total of $29.5 million, which also
resulted in a corresponding adjustment to the base rent for the
lease at the property.
In June 2022, we amended our lease with Sozo Health, Inc. (“Sozo”)
at one of our Michigan properties, increasing the improvement
allowance by approximately $1.2 million to a total of approximately
$7.0 million, which also resulted in a corresponding adjustment to
the base rent for the lease at the property.
In June 2022, we amended our lease with a subsidiary of Curaleaf at
one of our Pennsylvania properties, increasing the improvement
allowance by $35.0 million to a total of approximately $47.4
million, which also resulted in a corresponding adjustment to the
base rent for the lease at the property.
In June 2022, we amended our lease with a subsidiary of Green Thumb
at one of our Pennsylvania properties, increasing the improvement
allowance by $55.0 million to a total $74.3 million, which also
resulted in a corresponding adjustment to the base rent for the
lease at the property.
Including all of our properties, during the nine months ended
September 30, 2022, we capitalized costs of approximately $303.9
million and funded approximately $316.5 million relating to
improvements and construction activities at our properties.
Future contractual minimum rent (including base rent and property
management fees) under the operating leases as of September 30,
2022 for future periods is summarized as follows (in
thousands):
|
|
|
|
Year
|
|
Contractual Minimum Rent
|
2022 (three months ending December 31)
|
|
$
|
69,460
|
2023
|
|
|
287,080
|
2024
|
|
|
295,416
|
2025
|
|
|
304,199
|
2026
|
|
|
313,276
|
Thereafter
|
|
|
4,418,742
|
Total
|
|
$
|
5,688,173
|
7. Debt
Exchangeable
Senior Notes
As of September 30, 2022, our Operating Partnership had outstanding
approximately $6.4 million principal amount of 3.75% Exchangeable
Senior Notes due 2024 (the “Exchangeable Senior Notes”). The
Exchangeable Senior Notes are senior unsecured obligations of
our Operating Partnership, are fully and unconditionally guaranteed
by us and our Operating Partnership’s subsidiaries and are
exchangeable for cash, shares of our common stock, or a combination
of cash and shares of our common stock, at our Operating
Partnership’s option, at any time prior to the close of business on
the second scheduled trading day immediately preceding the stated
maturity date. The exchange rate for the Exchangeable Senior
Notes at September 30, 2022 was 15.86813 shares of our common
stock per $1,000 principal amount of Notes and the exchange
price at September 30, 2022 was approximately $63.02 per share of
our common stock. The exchange rate and exchange price are subject
to adjustment in certain circumstances. The Exchangeable Senior
Notes will pay interest semiannually on March 15 and September
15 of each year at a rate of 3.75% per annum and will mature on
February 21, 2024, unless earlier exchanged or repurchased in
accordance with their terms. Our Operating Partnership will not
have the right to redeem the Exchangeable Senior Notes prior
to maturity, but may be required to repurchase the Exchangeable
Senior Notes from holders under certain circumstances. At
September 30, 2022, the if-exchanged value of the Exchangeable
Senior Notes exceeded the principal amount by approximately $2.6
million.
During the three and nine months
ended September 30, 2022, we issued 265 and 413,166 shares, respectively, of our common stock
upon exchanges by holders of approximately $17,000 and $26.9 million, respectively, of outstanding
principal amount of our Exchangeable Senior Notes. For the nine
months ended September 30, 2022, we recognized a loss on the
exchange totaling approximately $125,000, resulting from the difference between the
fair value and carrying value of the debt as of the date of the
exchange. The issuance of the shares pursuant to the exchanges
resulted in a non-cash increase to our additional paid-in capital
account of approximately $17,000 and $26.7 million for the three and nine months ended
September 30, 2022, respectively.